Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
30

Summary

Conditions
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
  • Adult Acute Myeloid Leukemia With Del(5q)
  • Adult Acute Lymphoblastic Leukemia in Remission
  • Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
  • Chronic Neutrophilic Leukemia
  • Juvenile Myelomonocytic Leukemia
  • Adult Acute Myeloid Leukemia in Remission
  • Childhood Myelodysplastic Syndromes
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Waldenstrom Macroglobulinemia
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
  • Recurrent Childhood Acute Lymphoblastic Leukemia
  • Refractory Anemia With Ringed Sideroblasts
  • Recurrent Adult Acute Myeloid Leukemia
  • Recurrent/Refractory Childhood Hodgkin Lymphoma
  • Secondary Myelodysplastic Syndromes
  • Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
  • Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
  • Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
  • Recurrent Adult Acute Lymphoblastic Leukemia
  • Recurrent Marginal Zone Lymphoma
  • Recurrent Mycosis Fungoides/Sezary Syndrome
  • Mastocytosis
  • Recurrent Adult Hodgkin Lymphoma
  • Recurrent Grade 1 Follicular Lymphoma
  • Primary Myelofibrosis
  • Recurrent Grade 2 Follicular Lymphoma
  • Refractory Multiple Myeloma
  • Previously Treated Myelodysplastic Syndromes
  • Childhood Acute Myeloid Leukemia in Remission
  • Chronic Myelomonocytic Leukemia
  • Recurrent Childhood Acute Myeloid Leukemia
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • Recurrent Small Lymphocytic Lymphoma
  • Aplastic Anemia
  • Refractory Anemia
  • Refractory Hairy Cell Leukemia
  • T-cell Large Granular Lymphocyte Leukemia
  • Splenic Marginal Zone Lymphoma
  • Nodal Marginal Zone B-cell Lymphoma
  • Childhood Acute Lymphoblastic Leukemia in Remission
  • Chronic Eosinophilic Leukemia
  • Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
  • Recurrent Adult Grade III Lymphomatoid Granulomatosis
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

PRIMARY OBJECTIVES: I. To compare the overall survival (OS) rate at 2 years post treatment using the Jefferson 2 step reduced intensity conditioning (RIC) approach in patients with haploidentical family donors with hematological malignancies in morphological or radiographic remission or with chemose...

PRIMARY OBJECTIVES: I. To compare the overall survival (OS) rate at 2 years post treatment using the Jefferson 2 step reduced intensity conditioning (RIC) approach in patients with haploidentical family donors with hematological malignancies in morphological or radiographic remission or with chemosensitive, indolent diseases to historical OS rates in similar populations after RIC matched donor HSCT as reported in the literature. SECONDARY OBJECTIVES: I. To compare the treatment-related mortality (TRM) rate at 2 years for patients treated on this study to the historical TRM rates of patients undergoing RIC matched-sibling HSCT as reported in the literature. II. To compare the 2 year relapse rates and relapse related mortality of patients with myeloid diseases to that of patients with lymphoid diseases who are treated on this Thomas Jefferson University (TJU) RIC 2 step approach. III. To determine the incidence and severity of graft-versus-host disease (GVHD) in patients undergoing treated on the TJU RIC 2 step approach. IV. To evaluate engraftment rates and lymphoid reconstitution in patients treated on the TJU RIC 2 step approach. V. To evaluate the incidence of TRM at 100 days in patients treated on the TJU RIC 2 step approach. OUTLINE: REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate intravenously (IV) over 60 minutes on days -11 to -8 and bulsufan IV over 3 hours on days -10 to -9. Patients undergo total body irradiation (TBI) on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2. TRANSPLANTATION: Patients undergo donor lymphocyte infusion (DLI) on day -6 and cluster of differentiation (CD)-34+ allogeneic peripheral blood stem cell transplantation (PBSCT) on day 0. GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or orally (PO) with taper beginning on day 42. Patients also receive mycophenolate mofetil IV twice daily (BID) on days -1 to 28. After completion of study treatment, patients are followed up periodically for 2 years.

Tracking Information

NCT #
NCT01384513
Collaborators
Not Provided
Investigators
Principal Investigator: Dolores Grosso, DNP, CRNP Sidney Kimmel Cancer Center at Thomas Jefferson University Principal Investigator: Neal Flomenberg, MD Sidney Kimmel Cancer Center at Thomas Jefferson University